NeuroMax, LLC

“NeuroMax” is a private biotechnology company, founded in 2010, with the purpose to develop and launch in the Russian market innovative products for treatment of central and peripheral nervous system diseases. “NeuroMax” has been financed by Maxwell Biotech Venture Fund and has become a resident of Skolkovo Biomed Cluster as well as a participant of “Medicine of the Future” Technological platform. Projected drug, NM-IA-001, is the first and only Russian drug intended for the pathogenetic treatment of diabetic neuropathy. In preclinical proof of concept NM-IA-001 demonstrated high efficiency and a significant slowing of the disease course.